(Q35603105)

9 August 2017

1 reference

title

Part II: testicular cancer--management of advanced disease (English)

1 reference

9 August 2017

Robert H Jones

1

1 reference

9 August 2017

Paul A Vasey

series ordinal

2

1 reference

9 August 2017

publication date

1 December 2003

1 reference

Lancet Oncology Commission

9 August 2017

published in

1 reference

9 August 2017

volume

4

1 reference

9 August 2017

issue

12

1 reference

9 August 2017

page(s)

738-747

1 reference

Combination chemotherapy in germinal cell tumors

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

The role of maintenance therapy in disseminated testicular cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Clinical stage B non-seminomatous germ cell testis cancer: the Indiana University experience (1965-1989) using routine primary retroperitoneal lymph node dissection

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Prognostic factors for favorable outcome in disseminated germ cell tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Four cycles of BEP versus an alternating regime of PVB and BEP in patients with poor-prognosis metastatic testicular non-seminoma; a randomised study of the EORTC Genitourinary Tract Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indian University experience

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: a review of patients with germ cell tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Carbon monoxide diffusing capacity is a poor predictor of clinically significant bleomycin lung. New Zealand Clinical Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: an Eastern Cooperative Oncology Group trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Importance of bleomycin in combination chemotherapy for good-prognosis testicular nonseminoma: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumours: a randomised trial. Australian and New Zealand Germ Cell Trial Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multiinstitutional Medical Research Council/European Organization for Resear

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Management of intermediate-prognosis germ-cell cancer: results of a phase I/II study of Taxol-BEP

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of C

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

POMB/ACE chemotherapy for mediastinal germ cell tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Cisplatin, etoposide, and ifosfamide salvage therapy for refractory or relapsing germ cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Salvage chemotherapy in refractory germ cell tumors with etoposide (VP-16) plus ifosfamide plus high-dose cisplatin. A VIhP regimen

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

High-dose chemotherapy as salvage treatment in germ cell tumors: a multivariate analysis of prognostic variables

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem-cell rescue in patients with relapsed or refractory germ cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Early salvage therapy for germ cell cancer using high dose chemotherapy with autologous bone marrow support

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

High-dose treatment with carboplatin, etoposide, and ifosfamide followed by autologous stem-cell transplantation in relapsed or refractory germ cell cancer: a phase I/II study. The German Testicular Cancer Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumours. Preliminary results of a French randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Irinotecan in patients with relapsed or cisplatin-refractory germ cell cancer: a phase II study of the German Testicular Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Irinotecan plus cisplatin has substantial antitumor effect as salvage chemotherapy against germ cell tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Is postchemotherapy retroperitoneal surgery necessary in patients with nonseminomatous testicular cancer and minimal residual tumor masses?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

The role of adjunctive postchemotherapy surgery for nonseminomatous germ-cell tumors: current concepts and controversies

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Interdisciplinary consensus on diagnosis and treatment of testicular germ cell tumors: result of an update conference on evidence-based medicine (EBM).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Radiotherapy after chemotherapy for metastatic seminoma--a diminishing role. MRC Testicular Tumour Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Management of residual mass in advanced seminoma: results and recommendations from the Memorial Sloan-Kettering Cancer Center

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Predictive impact of 2-18fluoro-2-deoxy-D-glucose positron emission tomography for residual postchemotherapy masses in patients with bulky seminoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Surgical salvage of chemorefractory germ cell tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

Absence of c-KIT and members of the epidermal growth factor receptor family in refractory germ cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901279-8

7 January 2021

10.1016/S1470-2045(03)01279-8

Identifiers

DOI

1 reference

release_mwdcyz4ewverhgunaqamxqeike

9 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/mwdcyz4ewverhgunaqamxqeike

24 November 2022

mapped directly with Wikidata item

1 reference